These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11773299)

  • 41. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
    D'Andrea GM; Seidman AD
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of a scientific presentation on community treatment patterns for primary breast cancer.
    Giordano SH; Duan Z; Kuo YF; Hortobagyi GN; Freeman J; Goodwin JS
    J Natl Cancer Inst; 2006 Mar; 98(6):382-8. PubMed ID: 16537830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paclitaxel and docetaxel in the treatment of breast cancer.
    Saloustros E; Mavroudis D; Georgoulias V
    Expert Opin Pharmacother; 2008 Oct; 9(15):2603-16. PubMed ID: 18803448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [From conquering metastatic disease to adjuvant therapy: clinical evolution of docetaxel in breast cancer].
    Cartenì G
    Tumori; 2001; 87(6):A1-5. PubMed ID: 11995695
    [No Abstract]   [Full Text] [Related]  

  • 49. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
    Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Taxanes in the treatment of breast cancer: a prodigy comes of age.
    Miller KD; Sledge GW
    Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The expanding role of epirubicin in the treatment of breast cancer.
    Glück S
    Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes.
    Clemons M; Leahy M; Valle J; Jayson G; Ranson M; Howell A
    Eur J Cancer; 1997 Nov; 33(13):2183-93. PubMed ID: 9470804
    [No Abstract]   [Full Text] [Related]  

  • 54. [Taxanes in the treatment of breast and ovarian cancers: current indications and results].
    Espié M; Cuvier C; Gorins A; Marty M
    Contracept Fertil Sex; 1998 Nov; 26(11):805-11. PubMed ID: 9864888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
    Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
    Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.
    Araque Arroyo P; Ubago Pérez R; Cancela Díez B; Fernández Feijóo MA; Hernández Magdalena J; Calleja Hernández MA
    Cancer Treat Rev; 2011 Apr; 37(2):105-10. PubMed ID: 20655664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
    Sjöström J; Collan J; von Boguslawski K; Franssila K; Bengtsson NO; Mjaaland I; Malmström P; Østenstad B; Wist E; Valvere V; Bergh J; Skiöld-Petterson D; Saksela E; Blomqvist C
    Eur J Cancer; 2002 Mar; 38(4):535-42. PubMed ID: 11872346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Taxane containing regimens for metastatic breast cancer.
    Ghersi D; Wilcken N; Simes J; Donoghue E
    Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.
    Estévez LG; Muñoz M; Alvarez I; Fernández Y; García-Mata J; Ruiz-Borrego M; Tusquets I; Seguí MA; Rodríguez-Lescure A; Adrover E; Lluch A
    Cancer Treat Rev; 2007 Aug; 33(5):474-83. PubMed ID: 17561350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current status of taxanes as adjuvant therapy for early-stage breast cancer.
    Wolff AC
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):227-9. PubMed ID: 16468473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.